ScholarIQanswers from OpenAlex & ORCID
Stanley Cohen
ResearcherPublications, citations & collaboration network
Stanley Cohen is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Stanley Cohen have?
ScholarIQindexed works
Stanley Cohen has 273 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Stanley Cohen have?
ScholarIQcitation count
Stanley Cohen has 25,007 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Stanley Cohen?
ScholarIQh-index
Stanley Cohen has an h-index of 68 in OpenAlex.
What is the i10-index of Stanley Cohen?
ScholarIQi10-index
Stanley Cohen has an i10-index of 165 in OpenAlex.
What is the ORCID of Stanley Cohen?
ScholarIQorcid
The ORCID for Stanley Cohen is on the source record.
What is the OpenAlex record for Stanley Cohen?
ScholarIQopenalex
The OpenAlex for Stanley Cohen is on the source record.
What are the most-cited papers on Stanley Cohen?
ScholarIQmost cited works
The PREMIER study: A multicenter, randomized, double‐blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment
Ferdinand C. Breedveld, Michael H. Weisman, Arthur F. Kavanaugh, Stanley Cohen, Karel Pavelká, Ronald van Vollenhoven, John T. Sharp, John L. Perez, G Spencer-Green
Rituximab for rheumatoid arthritis refractory to anti–tumor necrosis factor therapy: Results of a multicenter, randomized, double‐blind, placebo‐controlled, phase III trial evaluating primary efficacy and safety at twenty‐four weeks
Stanley Cohen, Paul Emery, Maria Greenwald, Maxime Dougados, Richard Furie, Mark C. Genovese, Edward Keystone, J. Loveless, Gerd‐Rüdiger Burmester, Matthew Cravets, E. Hessey, T Shaw, Mark C. Totoritis
Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis
Ronald van Vollenhoven, Roy Fleischmann, Stanley Cohen, Eun Bong Lee, Juan A. García Meijide, Sylke Wagner, Šárka Forejtová, Samuel H. Zwillich, David Gruben, Tamás Koncz, Gene V. Wallenstein, Sriram Krishnaswami, John Bradley, Bethanie Wilkinson
Tofacitinib (CP‐690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelve‐month data from a twenty‐four–month phase III randomized radiographic study
Désirée van der Heijde, Yoshiya Tanaka, Roy Fleischmann, Edward Keystone, Joel M. Kremer, Cristiano A. F. Zerbini, Myrna Cardiel, Stanley Cohen, Peter Nash, Yeong Wook Song, Dana Tegzová, Bradley T. Wyman, David Gruben, Birgitta Benda, Gene V. Wallenstein, Sriram Krishnaswami, Samuel H. Zwillich, John Bradley, Carol A. Connell, and the ORAL Scan Investigators
A phase IIb dose‐ranging study of the oral JAK inhibitor tofacitinib (CP‐690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone
Joel M. Kremer, Stanley Cohen, Bethanie Wilkinson, Carol A. Connell, Jonathan French, Juan J. Gómez‐Reino, David Gruben, Keith S. Kanik, Sriram Krishnaswami, Virginia Pascual‐Ramos, Gene V. Wallenstein, Samuel H. Zwillich